limited or no options.
Research and Development
We focus on creating a thoughtful development strategy for every molecule and treatment we pursue, whether we partner with other leading organizations to study a new therapy or leverage our own research to usher a medicine from early stage development to patients in the marketplace.
We continue to invest in our growing research and development capabilities. We actively explore revolutionary drug options ranging from small molecule advancements to biologics, and novel compounds within neuroscience and oncology. This dynamic approach has allowed us to shepherd new medicines to market — from late-stage discovery through clinical development and regulatory approval.
- R/R AML or HMA Failure MDS3
- First-line, fit AML (Phase 1b)
- Low Intensity Therapy for first-line, unfit AML (Phase 1b)
- HR-MDS (EMSCO)5
- Newly diagnosed older adults with HR-AML4,5
- AML or HR-MDS >60 yrs (AML18)5
- AML or HR-MDS >18 yrs (AML19)5
- Newly diagnosed adults with standard- and HR-AML (AMLSG)5
- Newly diagnosed <22 yrs with AML (COG)5
Through Jazz’s patented CombiPlex® platform, Jazz is evaluating oncology combinations to support identification of clinical product candidate(s) and is leading a collaborative approach with partners to research and develop new therapies.